Oseltamivir reduces duration and complications of influenza
the ONA take:
According to a new study published in the journal The Lancet, researchers at the University of Michigan, the University of Alabama, and the London School of Hygiene and Tropical Medicine have found that oseltamivir, a neuraminidase inhibitor, decreases the duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
For the meta-analysis, researchers identified clinical trials conducted between 1997 and 2001. The studies included over 4,300 patients with more than half being treated with oseltamivir for influenza.
Results showed that when patients took oseltamivir 75mg twice daily within 36 hours of developing at least two flu symptoms, oseltamivir decreased the duration of the flu by 21%.
Patients who took oseltamivir experienced symptom alleviation at 98 hours versus 123 hours for those who took placebo.
In addition, researchers found that 4.9% of those who took oseltamivir had respiratory complications compared with 8.7% of those who took placebo. Oseltamivir was also shown to reduce hospital admissions by 63%. In regard to safety, oseltamivir increased nausea and vomiting, but did not cause more neurological or psychological disorders than placebo.
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|